It only had been about two months since I published my last article about the German pharmaceutical and life-science company Bayer Aktiengesellschaft ( BAYZF ). In the conclusion of my last article I wasMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to smal ...